Alpha Diagnostic International, Inc. Anti-Human beta-site APP cleaving enzyme (BACE/Asp2) antiserum #1 BACE11-S

Anti-Human beta-site APP cleaving enzyme (BACE/Asp2) antiserum #1 General Information -amyloid (A ) deposition in the brain is the hallmark of Alzheimer's Disease (AD). To initiate A formation, -secretase cleaves APP at the N-terminus of A to release APPs (~100 kDa soluble NT-fragment), and C99, a 12-kDa CT membrane fragment. Altern SugApplications Most Antibodies are tested by ELISA and Western. Additional applications, such as IHC or IP may have been tested and will be listed in the product data sheets or published research papers using our products. Typically, antibodies are tested against the SugSecAntibodies http://4adi.com/comm erce/ccc2480-seconda ry-antibodies-rabbit .htm SpeciesReactivity Human SugNegativeControl Non-immune Rabbit IgG Cat# 20009-1 Form Antiserum Unpurified SugPositiveControl Recombinant or naturally purified proteins or cells of tissues expressing the protein under study can be used as positive controls for Western or IHC. Please review the ?General Information? tan under Product overview section. Control or blocking peptid Antigen 17-aa peptide of Human BACE/Asp2 ; Designated (BACE11-P or control peptide) conjugated to KLH; epitope location ~ C-terminus SpCrossreactivity The human BACE11-P peptide sequence has high degree of homology (93%) with mouse and rat BACE/Asp2. No significant sequence homology exists with BACE2/Aps1, a homolog of BACE, or other Asps. Antibody crossreactivity in various species is not established For research use only, not for diagnostic or therapeutic use.